Synchronous cancer in patients with abdominal aortic aneurysm (AAA) increases morbidity and mortality after AAA repair. However, little is known about the impact of the history of cancer on mortality after AAA repair.
Methods
Patients with intact AAA who were treated with endovascular aneurysm repair or open surgical repair were selected from the Health Insurance and Review Assessment data in South Korea between 2007 and 2016. Primary endpoints included the 30- and 90-day mortality and long-term mortality after AAA repair. The Cox proportional hazards models were constructed to evaluate independent predictors of mortality.
Results
A total of 1999 patients (17.0%, 1999/11785) were diagnosed with cancer prior to the AAA repair. History of cancer generally had no effect in short-term mortality at 30 and 90 days. However, short-term mortality rate of patients with a history of lung cancer was more than twice that of patients without it (3.07% vs. 1.06%, P = 0.0038, 6.14% vs. 2.69%, P = 0.0016). Furthermore, the mortality rate at the end of the study period was significantly higher in AAA patients with a history of cancer than in those without a history of cancer (21.21% vs. 17.08%, P < .0001, HR, 1.31, 95% CI, 1.17–1.46).
Conclusions
The history of cancer in AAA patients increases long-term mortality but does not affect short-term mortality after AAA repair. However, AAA repair could increase both short- and long-term mortality in patients with lung cancer history, and those cases should be more carefully selected.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AAA
Abdominal aortic aneurysm
CCI
Charlson Cormorbidity Index
CI
Confidence intervals
COPD
Chronic obstructive pulmonary disease
ESRD
End-stage renal disease
EVAR
Endovascular aortic repair
HIRA
Health Insurance Review and Assessment Service
HR
Hazard ratios
ICD-10
International Classification of Diseases, Tenth Revision
OSR
Open surgical repair
Background
An asymptomatic abdominal aortic aneurysm (AAA) is usually found incidentally during workup for other clinical problems or on ultrasound during regular check-ups. Because cancer patients often undergo periodic imaging studies with computed tomography scan or ultrasound examinations, they have an increased diagnosis of AAA [1]. Therefore, physicians could encounter situations where the patients with AAA have a history of cancer [2]. However, there is limited information on how the history of malignancy affects the decision and short- and long-term outcome of AAA repair.
Many studies have analyzed the effect of AAA repair in patients with synchronous malignancy and showed increased short-term mortality and morbidity after both endovascular aortic repair (EVAR) and open surgical repair (OSR) [3]. In addition, patients with intra-abdominal tumors have increased perioperative mortality after OSR of AAA, and the history of intra-abdominal procedures may hinder OSR due to the development of adhesions [4]. Thus, EVAR may be the treatment of choice in cancer patients with suitable anatomy while its adequacy is yet to be determined.
Anzeige
Despite improvements in short-term outcome after AAA repair, long-term survival is still not favorable [5‐7]. End-stage renal disease (ESRD), chronic obstructive pulmonary disease (COPD), AAA diameter, and age at the time of surgery are known and unmodifiable risk factors affecting the survival after AAA repair [8]. A history of cancer can also affect the long-term survival of patients undergoing AAA repair [9]. Therefore, the risk and benefit of AAA repair should be carefully evaluated according to the patient’s life expectancy and potential risk factors [10].
The purpose of our study was to investigate the effect of cancer history on the outcome of AAA repair. In this retrospective study using big data, we first determined the incidence and types of cancer history in patients who underwent AAA repair. We then evaluated how cancer history affects short- and long-term mortality after AAA repair.
Methods
Patient and public involvement
The Health Insurance Review and Assessment Service (HIRA) reviews the accuracy of claims and renders reimbursement decisions for the National Health Insurance, covering approximately 98% of the entire South Korean population. We used the claims data of HIRA, comprised of detailed health care service information, including diagnosis, treatment, procedure, surgical history, and prescription drugs, along with the International Classification of Diseases, Tenth Revision (ICD-10) diagnosis codes [11].
From the HIRA data, a study cohort of patients diagnosed with AAA (I71.01, I71.3, I71.4, I71.5, I71.6, I71.8, I71.9) between January 1, 2007 and December 31, 2016 was created. Of the 79,880 eligible patients, 68,095 who were diagnosed with ruptured AAA (I71.3, I71.5, I71.8), untreated by EVAR or OSR, or had an unverified date of death were excluded. The death of a patient was designated as an “event,” and living patients were censored on December 31, 2016. The final sample included 11,785 patients with intact AAA treated by EVAR or OSR.
Anzeige
Patients with a history of cancer were defined as those diagnosed with malignant neoplasms (ICD-10 C00–97) more than two times prior to the EVAR or OSR. The main outcome measure was the all-cause mortality at 30 days, 90 days, and at the end of the study period following AAA repair in patients with and without a cancer history.
Variables of interest
The demographic variables included age (5-year increments: < 65, 65–69, 70–74, 75–79, 80–84, 85–89, versus ≥90) and sex (male versus female). Health insurance coverage was categorized into the National Health Insurance Program, a mandatory enrollment scheme, and the Medical Aid Program for low-income citizens. The hospitals where EVAR or OSR were performed ranged from small general hospitals with 100–300 beds to mid-sized general hospitals with 300–1000 beds to tertiary research university hospitals with over 1000 beds. The hospital locations were divided into urban and rural areas. The comorbidities were selected using the Charlson Comorbidity Index (CCI), a method of categorizing comorbidities based on the ICD-10 codes, and grouped based on the CCI scores 0–1, 2, and ≥ 3 [12]. Specific comorbidities included hypertension (ICD-10: I10), diabetes mellitus (ICD-10: E10, E11), myocardial infarction (ICD-10: I21, I22), and end-stage renal diseases (ICD-10: N18.5).
Statistical analysis
The statistical differences in the patient characteristics based on the history of cancer were computed using the Chi-square test. We compared the prevalence of all-cause mortality in AAA patients with and without a cancer history. All-cause mortality was calculated at 30 days, 90 days, and at the end of the study period after AAA repair. We used the Kaplan-Meier curves to depict the cumulative incidence of all-cause mortality. The statistical comparison between the survival of AAA patients with and without cancer history was performed using the log-rank test.
To estimate the effect of cancer on death in AAA patients treated by EVAR or OSR, we conducted univariate (crude) and multivariable (adjusted) Cox-proportional hazards regression analyses with respect to the occurrence of all-cause deaths. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the outcome were calculated in AAA patients with and without a cancer history. The Cox-proportional regression models were adjusted for the demographic variables (i.e., age and sex) in Model 1 and then further adjusted for all covariates (i.e., CCI, insurance type, hospital type, regional area, and comorbidities) in Model 2. All analyses were performed using the SAS 9.4 software (SAS Institute, Cary, NC, USA), and the statistical significance level was set at α = .05.
Results
A total of 11,785 patients with intact AAA were included in this study, of which 1999 patients (17.0%) had preexisting cancer. The distribution of different types of malignancy is shown in Table 1. There were 1515 intra-abdominal and 1067 digestive cancers. Stomach cancer (21.5%) was the most commonly diagnosed cancer, followed by colorectal (19.1%), prostate (18.4%), and lung cancer (11.5%).
Table 1
Types of malignancy
ICD code
Number
%
All sites
2315
Oral cavity & pharynx
C00–14
26
1.12
Digestive system
1067
46.09
Esophagus
C15
76
Stomach
C16
432
Small intestine
C17
9
Colon and rectum
C18, 19, 20
385
Anus, anal canal, & anorectum
C21
3
Liver & intrahepatic bile duct
C22
105
Gallbladder & other biliary
C23, 24
46
Pancreas
C25
40
Other digestive organs
C26
6
Thorax (including heart)
282
12.18
Lung & bronchus
C34
228
Other respiratory organs
C30–33, 35–39
56
Bones & joints
C40–41
3
0.13
Skin & soft tissue
C43–49
50
2.16
Breast
C50
26
1.12
Genital system
384
16.59
Uterine cervix
C53
11
Uterine corpus
C54, 55
1
Ovary
C56
1
Other genital, female
C51, 52, 57, 58
0
Prostate
C61
365
Testis
C62
4
Other genital, male
C60, 63
4
Urinary system
206
8.9
bladder
C67
114
Kidney & renal pelvis
C64, 65
90
Ureter & other urinary organs
C66, 68
16
Eye & orbit
C69
1
0.04
Brain & other nervous system
C70–72
4
0.17
Endocrine system
58
2.51
Thyroid
C73
57
Other endocrine
C74, 75
1
lymphoid neoplasms
50
2.16
Lymphoma
C81–86, 88
28
Myeloma
C90
10
Leukemia
C91–95
11
Other lymphoid
C96
2
Other & unspecified primary sites
C76–80, 97
158
6.83
Table 2 compares the characteristics of intact AAA patients with and without a cancer history. The AAA patients with cancer history were more likely to be older, male, with higher CCI scores, seek care in the urban area and have certain comorbidities (diabetes mellitus and dyslipidemia) compared to those without a cancer history. There was no difference in insurance type, hospital type, and comorbidities (hypertension, myocardial infarction, and ESRD) between the two groups.
Table 2
Characteristics of intact AAA patients with or without cancer
Table 3 shows the prevalence of all-cause mortality of AAA patients with and without a cancer history. In AAA patients treated by EVAR or OSR, the prevalence of all-cause mortality in the patients diagnosed with cancer was higher than in those without the diagnoses at the end of the study period (21.21% vs. 17.08%; P = <.0001). Total mortality was significantly higher in AAA patients with cancer history than in those without after EVAR (22.09% vs. 17.51%; P = 0.0010) and OSR (21.65% vs. 16.87%; P = 0.0054). Regardless of EVAR or OSR, there were no differences in 30-day and 90-day mortality between the two groups (P > .05).
Table 3
All-cause mortality rates in intact AAA patients with or without cancer
All-cause mortality
with cancer
without cancer
p-value
Patients with intact AAA treated by EVAR or OSR (n= 11,785)
30-day mortality
Censored
1980
(99.05)
9676
(98.88)
0.4967
Event
19
(0.95)
110
(1.12)
90-day mortality
Censored
1931
(96.60)
9529
(97.37)
0.0537
Event
68
(3.40)
257
(2.63)
Total mortality
Censored
1575
(78.79)
8115
(82.92)
<.0001
Event
424
(21.21)
1671
(17.08)
Patients with intact AAA treated by EVAR (n= 7903)
Fig. 1 represents the Kaplan-Meier curves for the cumulative incidence of overall mortality by a history of cancer. The AAA patients with cancer history had significantly higher mortality at the end of the study period (P < .0001) than in those without a cancer history. In contrast, 30-day and 90-day mortality rates in patients who underwent AAA repair did not differ based on the presence of cancer history.
Fig. 1
Kaplan-Meier survival curves for all-cause mortality in intact AAA patients by the presence of cancer: a All patients with intact AAA treated by EVAR or OSR, b Patients with intact AAA treated by EVAR, and c Patients with intact AAA treated by OSR
×
Anzeige
Table 4 shows the HRs for all-cause mortality of intact AAA patients with a cancer history. Among the AAA patients treated by EVAR or OSR, patients with cancer history showed significantly increased HRs for the total mortality (HR = 1.50; 95% CI, 1.35–1.67) than those without. After adjusting for potential covariates, the estimate decreased but remained for total mortality (HR = 1.31; 95% CI, 1.17–1.46). The risk of total mortality was similar in AAA patients treated with EVAR (adjusted HR = 1.28; 95% CI, 1.13–1.46) and those treated with OSR (adjusted HR = 1.33; 95% CI, 1.06–1.66). On the contrary, HRs for 30-day and 90-day mortality were not significant whether the patients with AAA had cancer or not.
Table 4
Hazard ratio for all-cause mortality associated with the presence of cancer in patients with intact AAA
All-cause mortality
Crude HR (95% CIs)
Adjusted HR (95% CIs)*
Model 1
Model 2
Patients with intact AAA treated by EVAR or OSR (n= 11,785)
30-day mortality
0.85
(0.52–1.38)
0.83
(0.50–1.36)
0.80
(0.49–1.31)
90-day mortality
1.30
(0.99–1.69)
1.20
(0.92–1.58)
1.16
(0.89–1.53)
Total mortality
1.50
(1.35–1.67)
1.31
(1.18–1.46)
1.31
(1.17–1.46)
Patients with intact AAA treated by EVAR (n= 7903)
30-day mortality
0.80
(0.45–1.43)
0.82
(0.46–1.46)
0.80
(0.45–1.43)
90-day mortality
1.19
(0.88–1.62)
1.17
(0.86–1.60)
1.14
(0.83–1.55)
Total mortality
1.40
(1.24–1.58)
1.29
(1.14–1.46)
1.28
(1.13–1.46)
Patients with intact AAA treated by OSR (n= 3882)
30-day mortality
1.02
(0.40–2.58)
0.96
(0.37–2.45)
0.87
(0.34–2.24)
90-day mortality
1.57
(0.90–2.73)
1.35
(0.77–2.36)
1.28
(0.73–2.24)
Total mortality
1.55
(1.24–1.94)
1.32
(1.06–1.65)
1.33
(1.06–1.66)
AAA Abdominal aortic aneurysm
*Model 1: Adjusted for age and sex
Model 2: Further adjusted for insurance type (National Health Insurance or Medical Aid Program), hospital type (tertiary hospital or general/small hospital), regional area (urban or rural), CCI (0–1, 2, or ≥ 3), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, or end-stage renal disease)
We also calculated HR according to the history of intra-abdominal and digestive cancers and lung cancers. There was a significant increase in HRs for long-term but not short-term mortality in patients with intra-abdominal and digestive cancer history (Tables 5 and 6). Interestingly, HRs for 30- and 90-day mortality as well as long-term mortality were significantly increased in patients with lung cancer history (Table 7).
Table 5
Hazard ratio for all-cause mortality associated with the presence of intra-abdominal cancer in intact AAA patients
All-cause mortality
Crude HR (95% CIs)
Adjusted HR (95% CIs)*
Model 1
Model 2
Patients with intact AAA treated by EVAR or OSR (n= 11,785)
30-day mortality
0.82
(0.47–1.44)
0.81
(0.46–1.41)
0.79
(0.45–1.38)
90-day mortality
0.98
(0.70–1.36)
1.18
(0.97–1.45)
0.87
(0.62–1.21)
Total mortality
1.41
(1.25–1.59)
1.21
(1.07–1.36)
1.21
(1.07–1.37)
Patients with intact AAA treated by EVAR (n= 7903)
30-day mortality
0.67
(0.33–1.33)
0.68
(0.34–1.36)
0.66
(0.33–1.33)
90-day mortality
0.86
(0.59–1.25)
0.83
(0.57–1.22)
0.80
(0.55–1.18)
Total mortality
1.34
(1.17–1.53)
1.21
(1.05–1.38)
1.21
(1.05–1.39)
Patients with intact AAA treated by OSR (n= 3882)
30-day mortality
1.43
(0.57–3.63)
1.38
(0.70–2.73)
1.28
(0.50–3.31)
90-day mortality
1.39
(0.72–2.67)
1.19
(0.61–2.31)
1.14
(0.59–2.22)
Total mortality
1.37
(1.06–1.78)
1.13
(0.87–1.47)
1.16
(0.89–1.51)
AAA Abdominal aortic aneurysm
*Model 1: Adjusted for age and sex
Model 2: Further adjusted for CCI (0–1, 2, or ≥ 3) insurance type (National Health Insurance or Medical Aid Program), hospital type (tertiary hospital or general/small hospital), regional area (urban or rural), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, or end-stage renal disease)
Table 6
Hazard ratio for all-cause mortality associated with the presence of digestive cancer in patients with intact AAA
All-cause mortality
Crude HR (95% CIs)
Adjusted HR (95% CIs)*
Model 1
Model 2
Patients with intact AAA treated by EVAR or OSR (n= 11,785)
30-day mortality
0.84
(0.44–1.61)
0.85
(0.44–1.62)
0.82
(0.43–1.57)
90-day mortality
1.10
(0.76–1.58)
1.04
(0.72–1.50)
1.00
(0.69–1.45)
Total mortality
1.45
(1.26–1.66)
1.30
(1.13–1.49)
1.31
(1.14–1.50)
Patients with intact AAA treated by EVAR (n= 7903)
30-day mortality
0.84
(0.41–1.76)
0.88
(0.42–1.82)
0.87
(0.21–3.59)
90-day mortality
1.06
(0.71–1.59)
1.05
(0.70–1.58)
1.03
(0.69–1.54)
Total mortality
1.38
(1.19–1.61)
1.30
(1.11–1.51)
1.31
(1.12–1.52)
Patients with intact AAA treated by OSR (n= 3882)
30-day mortality
0.87
(0.21–3.59)
0.89
(0.21–3.68)
0.55
(0.13–2.24)
90-day mortality
1.06
(0.43–2.62)
1.02
(0.41–2.51)
1.05
(0.55–2.00)
Total mortality
1.34
(0.97–1.85)
1.17
(0.85–1.62)
1.21
(0.87–1.67)
AAA Abdominal aortic aneurysm
*Model 1: Adjusted for age and sex
Model 2: Further adjusted for CCI (0–1, 2, or ≥ 3) insurance type (National Health Insurance or Medical Aid Program), hospital type (tertiary hospital or general/small hospital), regional area (urban or rural), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, or end-stage renal disease)
Table 7
Hazard ratio for all-cause mortality associated with the presence of lung cancer in patients with intact AAA
All-cause mortality
Crude HR (95% CIs)
Adjusted HR (95% CIs)*
Model 1
Model 2
Patients with intact AAA treated by EVAR or OSR (n= 11,785)
30-day mortality
2.93
(1.37–6.28)
2.98
(1.39–6.41)
2.97
(1.38–6.39)
90-day mortality
2.33
(1.37–3.99)
2.24
(1.31–3.84)
2.27
(1.33–3.89)
Total mortality
2.07
(1.62–2.65)
1.90
(1.49–2.43)
1.95
(1.52–2.49)
Patients with intact AAA treated by EVAR (n= 7903)
30-day mortality
2.85
(1.15–7.03)
3.05
(1.23–7.58)
3.04
(1.22–7.58)
90-day mortality
1.84
(0.94–3.58)
1.84
(0.94–3.58)
1.90
(0.97–3.71)
Total mortality
1.91
(1.44–2.54)
1.77
(1.33–2.36)
1.81
(1.36–2.41)
Patients with intact AAA treated by OSR (n= 3882)
30-day mortality
3.26
(0.79–13.47)
3.08
(0.74–12.79)
3.26
(0.78–13.67)
90-day mortality
4.09
(1.66–10.07)
3.57
(1.44–8.83)
3.69
(1.48–9.19)
Total mortality
2.33
(1.44–3.77)
2.25
(1.39–3.64)
2.29
(1.41–3.71)
AAA Abdominal aortic aneurysm
*Model 1: Adjusted for age and sex
Model 2: Further adjusted for insurance type (National Health Insurance or Medical Aid Program), hospital type (tertiary hospital or general/small hospital), regional area (urban or rural), CCI (0–1, 2, or ≥ 3), and comorbidities (hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, or end-stage renal disease)
Discussion
Of the 11,785 patients surgically treated for intact AAA, 1999 (17.0%) had a history of cancer. Stomach cancer (21.5%) was the most commonly diagnosed cancer, followed by colorectal (19.1%), prostate (18.4%), and lung cancer (11.5%). History of cancer did not affect 30- and 90-day mortality after both OSR and EVAR. However, long-term mortality after AAA repair was significantly higher in patients with cancer history than in those without cancer history (21.21% vs. 17.08%, HR 1.31; 95% CI, 1.17–1.46).
Cancer and AAA
Cancer patients are more likely to have imaging studies done during the course of treatment and thus incidentally found to have AAA. Our results showed that about 17% of patients who underwent AAA repair had a cancer diagnosis, and most of them were intra-abdominal cancers (74%). The types of cancer diagnosis in patients with AAA repair were similar to those in the general population [13, 14]. Tilson et al. showed a shared genetic link between cancer and AAA development [15]. On the other hand, more imaging tests also leads to an increased AAA discovery when considering the incidence and types of cancer.
Anzeige
As the progression in cancer treatment have been decreasing overall deaths related to cancer, vascular surgeons will more commonly see cases of AAA in cancer patients. Their history of cancer would become an important factor to consider in determining the treatment strategy.
Short-term mortality
Both OSR and EVAR of the intact AAA did not increase mortality in patients with a history of cancer. In contrast, previous study by Kouvelos et al. of AAA repair in patients with synchronous malignancy showed higher mortality and morbidity [3]. Since we looked at a history of cancer rather than synchronous cancer, there could have been a longer time interval between the cancer treatment and AAA repair. By the time of AAA repair, patients may have recovered from the previous illness and regained their full body condition. Moreover, terminal cancer patients do not benefit from AAA repair and would have been excluded from the analysis.
We hypothesized that previous abdominal surgery interferes with OSR and results in a worse outcome. Additional analyses were performed with codes corresponding to intra-abdominal and digestive cancers. Interestingly, there was no difference in short-term mortality after OSR (1.12%) versus EVAR (1.12%). While EVAR is considered the preferred choice for AAA repair in patients with a history of abdominal surgeries, OSR also seems to be safe if well planned.
Long-term mortality
Generally, elective AAA repair shows poor long-term survival despite improved short-term outcomes [5, 8]. Long-term mortality after AAA repair was significantly higher in patients with a history of cancer after adjusting age and sex, hospital type, CCI, hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, and ESRD. This high mortality was expected as cancer and cardiovascular disease, including AAA, are major causes of death [2]. Our results demonstrate that a history of cancer should also be considered in clinical decision-making in AAA repair in addition to well-known risk factors, such as ESRD and COPD [16].
Anzeige
Lung Cancer
Patients with a history of lung cancer had increased short-term mortality as well as long-term mortality after AAA repair. Among all cancers, lung cancer is well known to have the worst prognosis at an advanced stage in most cases. 80% of lung cancer is non-small cell type, and lobectomy or pneumonectomy is performed in operable patients [17, 18]. These surgeries often further deteriorate the patient’s condition, and AAA repair can be difficult in patients with lung cancer due to higher treatment-related mortality [19‐21]. Therefore, the high mortality at 30 and 90 days suggests the need for reevaluation of current indications for AAA repair and for further research.
Strengths & Limitations
Studies using big data are helpful in revealing an overall understanding when the specific diagnosis code is reliable, and the endpoint is well defined. In our study, HIRA data allowed analysis of a vast number of patients and specific variables, such as mortality, and ensured accuracy by using diagnosis codes.
Due to the inherent limitations of HIRA data, the cause of death, cancer stage, and types of cancer surgeries could not be determined. The cancer stage will affect long-term survival rather than a short-term result. When we analyzed the cause of death based on patient code at the finial hospitalization, the patients with cancer history had cancer-related code as a major diagnostic code. However, this result has not reported this study because it came from an indirect estimation. Further studies are needed to determine the exact cancer recurrence and death in patient with cancer history.
Patients and their family will suffer from double jeopardy due to cancer and AAA and wish to understand the short- and long-term prognosis [22]. In addition to reporting the poor long-term survival of AAA repair, our study identified a history of cancer as a significant risk factor [8, 23]. Although there is no difference in perioperative mortality rate, a poor long-term survival would be disappointing news for the patients.
Conclusion
Malignancy in AAA patients can complicate the disease course and treatment as well as outcome. History of cancer increases long-term mortality after AAA repair, but there is no difference in short-term mortality after both OSR and EVAR. Well-planned OSR and EVAR can be safely performed even in patients with intact AAA and history of intra-abdominal cancer. However, in patients with history of lung cancer, AAA repair could increase both short- and long-term mortality, and therefore, cases should be carefully selected.
Acknowledgements
Not applicable.
Ethics approval and consent to participate
This study was approved by the Seoul National University Hospital Institutional Review Board (1803–015-926). Informed consent was waived for this study by the Board.
Consent for publication
Not applicable.
Competing interests
The authors declare no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.
Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.
Update Chirurgie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.
